Antibodies in the therapy of colon cancer.

摘要: Clinical research in antibody-based cancer therapy has been driven for many years by the prospect of identifying cell-surface antigens with sufficiently restrictive tissue expression patterns to allow specific targeting antibody tumor tissue. Few if any such antibodies capable rapidly and efficiently solid tumors have identified. The main reasons this are based on inherent pharmacokinetics physiology IgG, immunoglobulin G molecule. Factors that may limit potential include accessibility antigen, affinity, molecular size, metabolism. Immunoglobulins evolved optimally protect an organism from foreign invaders rather than act as efficient carrier molecule therapeutic reagents. Despite these limitations, our growing understanding biologic physiologic principles underlie targeted led development a generation novel reagents first "positive" clinical trials. Recent strategies use colon focused (I) unmodified mouse IgG; (2) immune globulin delivery radioisotopes; toxins, molecules; (3) genetically engineered constructs redesigned uses; (4) humanized, nonimmunogenic IgG structures; (5) antigen targets tumors. Genetically provide exciting approach address subsequently overcome some problems identified IgG. These new should increase dose fraction localized versus normal thereby improve capacity. In contrast, immune-mediated cytotoxicity less dependent quantitative difference between nonlocalized fraction. Because antibodies, which direct host cytotoxic mechanisms, become activated only when bound one would not expect nonspecific toxic effects antibody. hypothesis alone can destroy solely directing mechanisms is just now being tested trials evaluating humanized antibodies.